Should I buy or sell Karyopharm Therapeutics stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KPTI shares. View KPTI analyst ratings or view top-rated stocks .

What is Karyopharm Therapeutics' stock price target for 2024?

6 brokers have issued 1-year target prices for Karyopharm Therapeutics' shares. Their KPTI share price targets range from $3.00 to $10.00. On average, they predict the company's stock price to reach $5.86 in the next year. This suggests a possible upside of 581.1% from the stock's current price. View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts .

How have KPTI shares performed in 2023?

Karyopharm Therapeutics' stock was trading at $3.40 on January 1st, 2023. Since then, KPTI shares have decreased by 74.7% and is now trading at $0.86. View the best growth stocks for 2023 here .

When is Karyopharm Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024. View our KPTI earnings forecast .

How were Karyopharm Therapeutics' earnings last quarter?

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.02. The firm earned $36.01 million during the quarter, compared to analyst estimates of $37.34 million.

What ETF holds Karyopharm Therapeutics' stock ?

iShares Genomics Immunology and Healthcare ETF holds 391,728 shares of KPTI stock, representing 0.49% of its portfolio.

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?

31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com . Michael Kauffman has an approval rating of 83% among the company's employees.

What other stocks do shareholders of Karyopharm Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA) , Gilead Sciences (GILD) , CRISPR Therapeutics (CRSP) , Alibaba Group (BABA) , Micron Technology (MU) , Invitae (NVTA) , Advanced Micro Devices (AMD) , AbbVie (ABBV) , Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY) .

Who are Karyopharm Therapeutics' major shareholders?

Karyopharm Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Avidity Partners Management LP (7.25%), Jacobs Levy Equity Management Inc. (2.05%), Barclays PLC (1.01%), Tejara Capital Ltd (0.94%), Tejara Capital Ltd (0.94%) and Northern Trust Corp (0.86%). Insiders that own company stock include Deepika Pakianathan, Garen G Bohlin , Jatin Shah , Mansoor Raza Mirza, Michael Kauffman , Michael Mano, Michael Mason , Reshma Rangwala, Richard A Paulson, Sharon Shacham , Sohanya Roshan Cheng, Stephen Mitchener and Stuart Poulton. View institutional ownership trends .

How do I buy shares of Karyopharm Therapeutics?

Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Karyopharm Therapeutics Stock Price, News & Analysis (NASDAQ:KPTI)

$0.86

+0.02 (+2.38%)

(As of 12/8/2023 ET)

Compare

Today's Range: $0.84
▼
$0.88
50-Day Range: $0.68
▼
$1.34
52-Week Range: $0.67
▼
$4.87

Volume: 731,389 shs
Average Volume: 2.28 million shs
Market Capitalization: $98.50 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $5.86

Karyopharm Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 581.1% Upside
$5.86 Price Target
Short Interest: Bearish
16.49% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.11
Upright™ Environmental Score
News Sentiment: -0.92
Based on 2 Articles This Week
Insider Trading: Acquiring Shares
$50,191 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($1.13) to ($0.94) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

509th out of 954 stocks

Biotechnology Industry

52nd out of 109 stocks

3.3

Analyst's Opinion

Consensus Rating
Karyopharm Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $5.86, Karyopharm Therapeutics has a forecasted upside of 581.1% from its current price of $0.86.
Amount of Analyst Coverage
Karyopharm Therapeutics has only been the subject of 3 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
16.49% of the outstanding shares of Karyopharm Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Karyopharm Therapeutics has a short interest ratio ("days to cover") of 16.3, which indicates bearish sentiment.
Change versus previous month
Short interest in Karyopharm Therapeutics has recently increased by 5.47%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Karyopharm Therapeutics does not currently pay a dividend.
Dividend Growth
Karyopharm Therapeutics does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Karyopharm Therapeutics has received a 71.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Other cancer medication", "Clinical research services for physical health", and "Basic medical research services" products. See details.
Environmental Sustainability
The Environmental Impact score for Karyopharm Therapeutics is -1.11.

1.2

News and Social Media Coverage

News Sentiment
Karyopharm Therapeutics has a news sentiment score of -0.92. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 2 news articles for Karyopharm Therapeutics this week, compared to 2 articles on an average week.
Search Interest
6 people have searched for KPTI on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Karyopharm Therapeutics insiders have bought 367.46% more of their company's stock than they have sold. Specifically, they have bought $50,191.00 in company stock and sold $10,737.00 in company stock.
Percentage Held by Insiders
Only 3.32% of the stock of Karyopharm Therapeutics is held by insiders.
Percentage Held by Institutions
70.47% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($1.13) to ($0.94) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Karyopharm Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Karyopharm Therapeutics is -0.65, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

See Top Rated MarketRank™ Stocks Here

About Karyopharm Therapeutics Stock (NASDAQ:KPTI)

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). The company is also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.

KPTI Stock Price History

30 days | 90 days | 365 days | Advanced Chart

KPTI Stock News Headlines

December 6, 2023 | finance.yahoo.com

Great week for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) institutional investors after losing 84% over the previous year

November 29, 2023 | seekingalpha.com

Karyopharm Therapeutics; Promising Potential With 3 Ongoing Phase 3 Studies But Risky

December 8, 2023 | Edge On The Street (Ad)

Hunting for Domestic Vanadium - The U.S. Govt. Did WHAT?

A little-known metal called vanadium is vital to American national security and energy independence. But right now, China and Russia dominate our supply. The U.S. Govt. is so serious about vanadium, it funded and recently completed an "Earth MRI" survey to seek out new sources of this energy metal - in Wyoming.

November 16, 2023 | bizjournals.com

The Petri Dish: Concerns mar Verve data; Alnylam-Roche drug shows promise

November 6, 2023 | markets.businessinsider.com

Hold Rating on Karyopharm Therapeutics: Evaluating Q3 Results, Impact of PAP and Prospects of Xpovio in Myelofibrosis Treatment

November 6, 2023 | markets.businessinsider.com

Karyopharm : Data In Selinexor-Treated Patients With Endometrial Cancer Shows Improvements In PFS

November 6, 2023 | msn.com

Karyopharm reports encouraging data for endometrial cancer drug candidate

November 6, 2023 | finance.yahoo.com

Karyopharm Announces New Preliminary Data in Overall Survival (OS) in Selinexor-Treated Patients with Advanced or Recurrent TP53 Wild-Type Endometrial Cancer as Part of Pre-Specified Exploratory Subgroup Analysis of the SIENDO Study

December 8, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 3, 2023 | markets.businessinsider.com

Buy Rating Recommended for Karyopharm Therapeutics Amid Strong 3Q Results and Promising Xpovio Sales

November 3, 2023 | finance.yahoo.com

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q3 2023 Earnings Call Transcript

November 2, 2023 | msn.com

Karyopharm Therapeutics GAAP EPS of -$0.30 misses by $0.05, revenue of $36M misses by $1.4M

November 2, 2023 | finance.yahoo.com

Karyopharm Announces Presentations at the 65th American Society of Hematology Annual Meeting and Exposition (ASH)

November 2, 2023 | finance.yahoo.com

Karyopharm Therapeutics Inc (KPTI) Reports Q3 2023 Earnings, Total Revenue of $36.0 Million

November 2, 2023 | finance.yahoo.com

Karyopharm Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 2, 2023 | msn.com

Karyopharm Therapeutics Q3 2023 Earnings Preview

November 1, 2023 | markets.businessinsider.com

Here's what Wall Street expects from Karyopharm Therapeutics's earnings report

October 30, 2023 | msn.com

Karyopharm, Bristol Myers to evaluate drug combination for treatment of multiple myeloma

October 26, 2023 | finance.yahoo.com

Karyopharm to Report Third Quarter 2023 Financial Results on November 2, 2023

October 17, 2023 | fool.com

Karyopharm Therapeutics (NASDAQ: KPTI)

September 29, 2023 | markets.businessinsider.com

Analysts Are Bullish on These Healthcare Stocks: Karyopharm Therapeutics (KPTI), Pliant Therapeutics (PLRX)

September 26, 2023 | finance.yahoo.com

Karyopharm to Present Selinexor Data at the 2023 International Myeloma Society Annual Meeting and European Society of Gynaecological Oncology 2023 Annual Meetings

September 1, 2023 | finance.yahoo.com

Karyopharm Appoints Zhen Su, MD, MBA to its Board of Directors

August 21, 2023 | msn.com

Karyopharm Therapeutics: Seeking Upside Potential But Catalysts Too Far Away

August 4, 2023 | msn.com

Piper Sandler Maintains Karyopharm Therapeutics (KPTI) Overweight Recommendation

August 3, 2023 | benzinga.com

6 Analysts Have This to Say About Karyopharm Therapeutics

August 3, 2023 | finance.yahoo.com

Dozens more biotech jobs axed as two firms make cuts

See More Headlines

Receive KPTI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/02/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/21/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:KPTI
CUSIP: N/A
CIK: 1503802
Web: www.karyopharm.com
Phone: (617) 658-0600
Fax: N/A
Employees: 385
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $5.86
High Stock Price Target: $10.00
Low Stock Price Target: $3.00
Potential Upside/Downside: +579.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.32)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-165,290,000.00
Net Margins: -95.82%
Pretax Margin: -95.64%
Return on Equity: N/A
Return on Assets: -44.66%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.24
Quick Ratio: 4.19

Sales & Book Value

Annual Sales: $145.87 million
Price / Sales: 0.68
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($0.15) per share
Price / Book: -5.75

Miscellaneous

Outstanding Shares: 114,534,000
Free Float: 110,731,000
Market Cap: $98.72 million
Optionable: Optionable
Beta: -0.18

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Mr. Richard A. Paulson M.B.A. (Age 56)
President, CEO & Director
Comp: $1.36M
Dr. Sharon Shacham M.B.A. (Age 53)
Ph.D., Co-Founder & Chairman of Scientific Advisory Board
Comp: $1.4M
Mr. Michael P. Mason CPA (Age 48)
M.B.A., Executive VP, CFO & Treasurer
Comp: $681.59k
Mr. Michael J. Mano J.D. (Age 46)
Senior VP, General Counsel & Secretary
Comp: $625.08k
Ms. Sohanya Cheng M.B.A. (Age 40)
Executive VP & Chief Commercial Officer
Comp: $664.3k
Mr. Stuart Poulton
Executive VP & Chief Development Officer
Dr. Mansoor Raza Mirza M.D. (Age 62)
Clinical Consultant, Member of Scientific Advisory Board & Independent Director
Comp: $150k
Mr. Cameron Peters (Age 63)
Vice President of Finance, Assistant Treasurer & Principal Accounting Officer
Ms. Elhan Webb C.F.A.
Senior Vice President of Investor Relations
Mr. James Accumanno J.D.
Chief Compliance Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

KPTI Stock Analysis - Frequently Asked Questions

Should I buy or sell Karyopharm Therapeutics stock right now?: 6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" KPTI shares.
View KPTI analyst ratings or view top-rated stocks.
What is Karyopharm Therapeutics' stock price target for 2024?: 6 brokers have issued 1-year target prices for Karyopharm Therapeutics' shares. Their KPTI share price targets range from $3.00 to $10.00. On average, they predict the company's stock price to reach $5.86 in the next year. This suggests a possible upside of 581.1% from the stock's current price.
View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts.
How have KPTI shares performed in 2023?: Karyopharm Therapeutics' stock was trading at $3.40 on January 1st, 2023. Since then, KPTI shares have decreased by 74.7% and is now trading at $0.86.
View the best growth stocks for 2023 here.
When is Karyopharm Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 21st 2024.
View our KPTI earnings forecast.
How were Karyopharm Therapeutics' earnings last quarter?: Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its quarterly earnings data on Thursday, November, 2nd. The company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.28) by $0.02. The firm earned $36.01 million during the quarter, compared to analyst estimates of $37.34 million.
What ETF holds Karyopharm Therapeutics' stock ?: iShares Genomics Immunology and Healthcare ETF holds 391,728 shares of KPTI stock, representing 0.49% of its portfolio.

What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO?: 31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees.
What other stocks do shareholders of Karyopharm Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY).
Who are Karyopharm Therapeutics' major shareholders?: Karyopharm Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Avidity Partners Management LP (7.25%), Jacobs Levy Equity Management Inc. (2.05%), Barclays PLC (1.01%), Tejara Capital Ltd (0.94%), Tejara Capital Ltd (0.94%) and Northern Trust Corp (0.86%). Insiders that own company stock include Deepika Pakianathan, Garen G Bohlin, Jatin Shah, Mansoor Raza Mirza, Michael Kauffman, Michael Mano, Michael Mason, Reshma Rangwala, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener and Stuart Poulton.
View institutional ownership trends.
How do I buy shares of Karyopharm Therapeutics?: Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:KPTI) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Karyopharm Therapeutics Stock Price, News & Analysis (NASDAQ:KPTI)

Karyopharm Therapeutics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Karyopharm Therapeutics Stock (NASDAQ:KPTI)

KPTI Stock Price History

KPTI Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

KPTI Stock Analysis - Frequently Asked Questions

Overall MarketRank^™